V 212

Drug Profile

V 212

Alternative Names: Inactivated varicella-zoster vaccine - Merck; V212; Varicella zoster virus vaccine - Merck; VZV vaccine - Merck

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Merck & Co
  • Class Varicella vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Herpes zoster

Most Recent Events

  • 24 Feb 2017 Efficacy and adverse events data from a phase III trial in Herpes zoster released by Merck and Co
  • 29 May 2015 No recent reports on development identified - Phase-II for Herpes zoster (Prevention) in Australia, Canada, Denmark and Israel (SC)
  • 01 May 2015 V212 is still in phase III trials for Herpes zoster (Prevention) in countries worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top